Creutzfeldt-Jakob disease – CJD – is one of the prion diseases which occurs in humans and certain other animal species. There are a number of categories of CJD, including variant CJD – VCJD – which is linked to the Bovine Spongiform Encephalopathy – BSE – agent in cattle. Worldwide, there are documented cases of CJD being transmitted accidentally to patients via contaminated medical instruments or contaminated pituitary hormones prepared from human cadavers. These are known as iatrogenic infections. No cases of iatrogenic CJD infection has been notified to the Department of Health and Children in Ireland.
The emergence of VCJD has led to considerable scientific research into the nature of transmission of this condition. The nature of VCJD means that it is possible for transmission through hospital instruments or appliances although no case of transmission by this means has been identified.
The CJD advisory group was established in September 1996 to advise the Minister for Health and Children on all issues relating to CJD and to provide advice on particular issues referred by the Minister to the group from time to time. Included in the terms of reference of the advisory group is the surveillance of CJD in Ireland, the assessment of scientific developments, both nationally and internationally with regard to the risks to public health concerning Transmissible Spongiform Encephalopathy agents – TSEs – and CJD and the provision of advice on research strategies for BSE-CJD.
Additional InformationThe chairman of the group is Professor William Hall, virologist, virus reference laboratory, University College, Dublin, and the group currently consists of experts in, inter alia, public health, neuro-pathology, haematology, food safety and veterinary science.
At meetings in 1998 and 1999 the advisory group considered the recently published UK guidance, Transmissible Spongiform Encephalopathy Agents: Safe Working and the Prevention of Infection – prepared by the joint working group of the advisory committee on dangerous pathogens – ACDP – and the spongiform encephalopathy advisory committee – SEAC – on safe working and the prevention of infection relating to TSEs. The guidance deals with the risks from exposure to TSE agents that may arise as a result of work activities and it provides advice and recommendations on the minimisation of such risks and other related matters. It also addresses concerns about hospital infection control procedures and safe working in clinical settings.
On the advice of the advisory group a copy of the guidance was circulated to the chief executive officers of the health boards and the chief executive officers of the voluntary hospitals from the Chief Medical Officer of my Department last year. The CJD advisory group continues to keep abreast of scientific developments in this area.